Clinical significance of telomerase activity in multiple myeloma

Motoaki Shiratsuchi, Koichiro Muta, Yasunobu Abe, Seiichi Motomura, Fumihiro Taguchi, Hiroshi Takatsuki, Naokuni Uike, Tsukuru Umemura, Hajime Nawata, Junji Nishimura

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

BACKGROUND. The clinical course of patients with multiple myeloma varies, and therefore it is important to evaluate the disease state. We studied the telomerase activity of myeloma cells as a possible prognostic factor in such patients. METHODS. Twenty five samples from patients with multiple myeloma were studied. We purified myeloma cells in bone marrow samples according to the expression of surface antigens, CD38 and CD45. CD38+/CD45- or dim cells had morphologic characteristics of myeloma cells, with a purity exceeding 95%. The telomerase activity of myeloma cells was determined by a polymerase chain reaction-based telomeric repeat amplification protocol assay. Ki-67 positivity of the purified cells was determined by flow cytometry using anti-Ki-67 antibody. The relationship between telomerase activity and prognostic factors was also examined. RESULTS. A significantly high degree of telomerase activity was detected in subjects with a serum β2-microglobulin level ≥ 6mg/dL or at Stage III (P = 0.002). The serum C-reactive protein, lactate dehydrogenase, and creatinine levels did not correlate with the telomerase activity, but this activity did significantly correlate with Ki-67 positivity and the percentage of plasma cells in the bone marrow (r = 0.561, P = 0.004, and r = 0.397, P = 0.049, respectively). The patients with high levels of telomerase activity were thus found to have a significantly short survival time after sampling (P = 0.035). CONCLUSIONS. The measurement of the telomerase activity in myeloma cells was found to be a reliable marker for the proliferating capacity and tumor mass in myeloma patients. The telomerase activity of myeloma cells may therefore be useful as a prognostic factor.

Original languageEnglish
Pages (from-to)2232-2238
Number of pages7
JournalCancer
Volume94
Issue number8
DOIs
Publication statusPublished - Apr 15 2002

Fingerprint

Telomerase
Multiple Myeloma
Surface Antigens
Plasma Cells
L-Lactate Dehydrogenase
Bone Marrow Cells
C-Reactive Protein
Blood Proteins
Creatinine
Flow Cytometry
Bone Marrow
Polymerase Chain Reaction
Survival
Antibodies
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Shiratsuchi, M., Muta, K., Abe, Y., Motomura, S., Taguchi, F., Takatsuki, H., ... Nishimura, J. (2002). Clinical significance of telomerase activity in multiple myeloma. Cancer, 94(8), 2232-2238. https://doi.org/10.1002/cncr.10472

Clinical significance of telomerase activity in multiple myeloma. / Shiratsuchi, Motoaki; Muta, Koichiro; Abe, Yasunobu; Motomura, Seiichi; Taguchi, Fumihiro; Takatsuki, Hiroshi; Uike, Naokuni; Umemura, Tsukuru; Nawata, Hajime; Nishimura, Junji.

In: Cancer, Vol. 94, No. 8, 15.04.2002, p. 2232-2238.

Research output: Contribution to journalArticle

Shiratsuchi, M, Muta, K, Abe, Y, Motomura, S, Taguchi, F, Takatsuki, H, Uike, N, Umemura, T, Nawata, H & Nishimura, J 2002, 'Clinical significance of telomerase activity in multiple myeloma', Cancer, vol. 94, no. 8, pp. 2232-2238. https://doi.org/10.1002/cncr.10472
Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H et al. Clinical significance of telomerase activity in multiple myeloma. Cancer. 2002 Apr 15;94(8):2232-2238. https://doi.org/10.1002/cncr.10472
Shiratsuchi, Motoaki ; Muta, Koichiro ; Abe, Yasunobu ; Motomura, Seiichi ; Taguchi, Fumihiro ; Takatsuki, Hiroshi ; Uike, Naokuni ; Umemura, Tsukuru ; Nawata, Hajime ; Nishimura, Junji. / Clinical significance of telomerase activity in multiple myeloma. In: Cancer. 2002 ; Vol. 94, No. 8. pp. 2232-2238.
@article{e529c265db5e45f195d04e072e48f938,
title = "Clinical significance of telomerase activity in multiple myeloma",
abstract = "BACKGROUND. The clinical course of patients with multiple myeloma varies, and therefore it is important to evaluate the disease state. We studied the telomerase activity of myeloma cells as a possible prognostic factor in such patients. METHODS. Twenty five samples from patients with multiple myeloma were studied. We purified myeloma cells in bone marrow samples according to the expression of surface antigens, CD38 and CD45. CD38+/CD45- or dim cells had morphologic characteristics of myeloma cells, with a purity exceeding 95{\%}. The telomerase activity of myeloma cells was determined by a polymerase chain reaction-based telomeric repeat amplification protocol assay. Ki-67 positivity of the purified cells was determined by flow cytometry using anti-Ki-67 antibody. The relationship between telomerase activity and prognostic factors was also examined. RESULTS. A significantly high degree of telomerase activity was detected in subjects with a serum β2-microglobulin level ≥ 6mg/dL or at Stage III (P = 0.002). The serum C-reactive protein, lactate dehydrogenase, and creatinine levels did not correlate with the telomerase activity, but this activity did significantly correlate with Ki-67 positivity and the percentage of plasma cells in the bone marrow (r = 0.561, P = 0.004, and r = 0.397, P = 0.049, respectively). The patients with high levels of telomerase activity were thus found to have a significantly short survival time after sampling (P = 0.035). CONCLUSIONS. The measurement of the telomerase activity in myeloma cells was found to be a reliable marker for the proliferating capacity and tumor mass in myeloma patients. The telomerase activity of myeloma cells may therefore be useful as a prognostic factor.",
author = "Motoaki Shiratsuchi and Koichiro Muta and Yasunobu Abe and Seiichi Motomura and Fumihiro Taguchi and Hiroshi Takatsuki and Naokuni Uike and Tsukuru Umemura and Hajime Nawata and Junji Nishimura",
year = "2002",
month = "4",
day = "15",
doi = "10.1002/cncr.10472",
language = "English",
volume = "94",
pages = "2232--2238",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Clinical significance of telomerase activity in multiple myeloma

AU - Shiratsuchi, Motoaki

AU - Muta, Koichiro

AU - Abe, Yasunobu

AU - Motomura, Seiichi

AU - Taguchi, Fumihiro

AU - Takatsuki, Hiroshi

AU - Uike, Naokuni

AU - Umemura, Tsukuru

AU - Nawata, Hajime

AU - Nishimura, Junji

PY - 2002/4/15

Y1 - 2002/4/15

N2 - BACKGROUND. The clinical course of patients with multiple myeloma varies, and therefore it is important to evaluate the disease state. We studied the telomerase activity of myeloma cells as a possible prognostic factor in such patients. METHODS. Twenty five samples from patients with multiple myeloma were studied. We purified myeloma cells in bone marrow samples according to the expression of surface antigens, CD38 and CD45. CD38+/CD45- or dim cells had morphologic characteristics of myeloma cells, with a purity exceeding 95%. The telomerase activity of myeloma cells was determined by a polymerase chain reaction-based telomeric repeat amplification protocol assay. Ki-67 positivity of the purified cells was determined by flow cytometry using anti-Ki-67 antibody. The relationship between telomerase activity and prognostic factors was also examined. RESULTS. A significantly high degree of telomerase activity was detected in subjects with a serum β2-microglobulin level ≥ 6mg/dL or at Stage III (P = 0.002). The serum C-reactive protein, lactate dehydrogenase, and creatinine levels did not correlate with the telomerase activity, but this activity did significantly correlate with Ki-67 positivity and the percentage of plasma cells in the bone marrow (r = 0.561, P = 0.004, and r = 0.397, P = 0.049, respectively). The patients with high levels of telomerase activity were thus found to have a significantly short survival time after sampling (P = 0.035). CONCLUSIONS. The measurement of the telomerase activity in myeloma cells was found to be a reliable marker for the proliferating capacity and tumor mass in myeloma patients. The telomerase activity of myeloma cells may therefore be useful as a prognostic factor.

AB - BACKGROUND. The clinical course of patients with multiple myeloma varies, and therefore it is important to evaluate the disease state. We studied the telomerase activity of myeloma cells as a possible prognostic factor in such patients. METHODS. Twenty five samples from patients with multiple myeloma were studied. We purified myeloma cells in bone marrow samples according to the expression of surface antigens, CD38 and CD45. CD38+/CD45- or dim cells had morphologic characteristics of myeloma cells, with a purity exceeding 95%. The telomerase activity of myeloma cells was determined by a polymerase chain reaction-based telomeric repeat amplification protocol assay. Ki-67 positivity of the purified cells was determined by flow cytometry using anti-Ki-67 antibody. The relationship between telomerase activity and prognostic factors was also examined. RESULTS. A significantly high degree of telomerase activity was detected in subjects with a serum β2-microglobulin level ≥ 6mg/dL or at Stage III (P = 0.002). The serum C-reactive protein, lactate dehydrogenase, and creatinine levels did not correlate with the telomerase activity, but this activity did significantly correlate with Ki-67 positivity and the percentage of plasma cells in the bone marrow (r = 0.561, P = 0.004, and r = 0.397, P = 0.049, respectively). The patients with high levels of telomerase activity were thus found to have a significantly short survival time after sampling (P = 0.035). CONCLUSIONS. The measurement of the telomerase activity in myeloma cells was found to be a reliable marker for the proliferating capacity and tumor mass in myeloma patients. The telomerase activity of myeloma cells may therefore be useful as a prognostic factor.

UR - http://www.scopus.com/inward/record.url?scp=0037089647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037089647&partnerID=8YFLogxK

U2 - 10.1002/cncr.10472

DO - 10.1002/cncr.10472

M3 - Article

C2 - 12001122

AN - SCOPUS:0037089647

VL - 94

SP - 2232

EP - 2238

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -